FreshRSS

🔒
☐ ☆ ✇ BMJ Open

Understanding opioid use within the substance use journeys of adults receiving treatment: a qualitative study protocol of the participant-led timeline mapping approach

Por: Estrella · M. J. · Wells · S. · Foy · R. · Quilty · L. · Bozinoff · N. · Buckley · L. · Lincoln · S. · Patenaude · S. · Ali · F. — Enero 29th 2026 at 14:19
Introduction

The opioid crisis remains a significant public health emergency. Key contributors to this crisis include an increasingly toxic drug supply and inadequate health policies that rely on strategies to address opioid-related harms and underutilise primary prevention and early intervention approaches. To inform comprehensive prevention and early intervention strategies, research is needed to explore pathways involving hazardous opioid use (ie, daily opioid use that results in, and may arise from, disruptions to health, relationships, work or social functioning) and the individual, social and structural factors that shape such pathways. This qualitative study aims to address this research gap by exploring the substance use journeys of adults with lived or living experiences of hazardous opioid use who are receiving substance use treatment at a large Canadian mental health hospital.

Methods and analysis

A qualitative descriptive study informed by the life course perspective will be conducted. Data will be collected using participant-led timeline mapping in combination with semistructured interviews. Participants will include 20–30 adults who are receiving or have received substance use treatment from the hospital where the study is being conducted. Timelines and interviews will be analysed using thematic analysis. A brief demographic questionnaire will also be administered to describe characteristics of the sample.

Ethics and dissemination

Ethical approval was granted on 1 October 2025 by the Centre for Addiction and Mental Health Research Ethics Board (Protocol no. 2025/026). Findings will be reported through peer-reviewed publications, lay language reports and/or academic conferences on mental health and substance use health research.

☐ ☆ ✇ PLOS ONE Medicine&Health

Clinical assessment of transplacental transfer of maternal SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins: A chemiluminescence microparticle immunoassay study

Por: Elora Sharmin · Ajmain Ishaat Khan · Sheikh Foyez Ahmed — Noviembre 13th 2025 at 15:00

by Elora Sharmin, Ajmain Ishaat Khan, Sheikh Foyez Ahmed

Understanding the safety and efficacy of COVID-19 vaccines in pregnant women and their neonates is crucial for understanding maternal and fetal outcomes, particularly the extent of passive immunity against SARS-CoV-2 which can be imparted to the neonates. The purpose of this study was to evaluate the transplacental transfer of maternal SARS-CoV-2 IgG antibodies against the spike (S) and nucleocapsid (N) proteins to neonates and understand whether factors like maternal comorbidities, gestational weeks, and neonatal birth weight have an influence on placental transfer ratios (PTR). A total of 57 pregnant women were assessed for SARS-CoV-2-specific IgG antibodies at delivery, and corresponding antibody titers were also measured in their neonates immediately after delivery. The PTRs for anti-S and anti-N IgG were calculated, and statistical analyses were performed for identifying potential influencing factors. The mean PTR for anti-S IgG was 1.38, suggesting effective placental transfer, whereas anti-N IgG had a lower PTR of 1.13, indicating limited transfer. A strong positive correlation was observed between maternal and neonatal anti-S IgG (r = 0.558, p 
❌